Pasithea Updates Timelines for Cancer Clinical Trials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Should l Buy KTTA?
Pasithea Therapeutics provided updated timelines on its ongoing clinical trials in advanced cancer and adult NF1-PN patients. Ongoing Phase 1/1b clinical trial in adult patients with NF1-PN: Pasithea has completed enrollment of 12 patients through the first 4 dose cohorts in Part A of the study. The Company plans to present data in the second half of 2026, including available efficacy data through the six-month timepoint for both plexiform and cutaneous neurofibromas. The planned data release is also expected to include safety, tolerability and pharmacokinetic data. Ongoing Phase 1 clinical trial in advanced cancer patients: Pasithea expects to present longer-term follow-up data from patients in Cohort 4 through Cohort 8 in the second quarter of 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KTTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KTTA
Wall Street analysts forecast KTTA stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.794
Low
3.00
Averages
3.00
High
3.00
Current: 0.794
Low
3.00
Averages
3.00
High
3.00
About KTTA
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pasithea Appoints New CMO to Advance PAS-004 Development
- Executive Appointment: Pasithea Therapeutics has appointed Kartik Krishnan as Chief Medical Officer, who will oversee clinical strategy and development with a focus on neurofibromatosis type 1-associated tumors, which is expected to accelerate the development of its lead candidate PAS-004.
- R&D Experience: Krishnan brings over 20 years of experience in clinical development, regulatory strategy, and R&D, having previously worked at OncoNano Medicines, Arcus Biosciences, Genentech, and Amgen, and his experience in developing the FDA-approved MEK inhibitor cobimetinib is anticipated to directly benefit the progression of the PAS-004 program.
- Clinical Trial Progress: Pasithea is currently evaluating PAS-004 in early-stage clinical trials targeting advanced cancers and NF1-related plexiform neurofibromas, indicating the company's potential in the cancer treatment arena.
- Market Outlook: With ongoing evaluations of PAS-004, Pasithea may secure a significant position in the tumor treatment market, particularly in innovative therapies targeting NF1, thereby enhancing its competitive edge.
See More
Pasithea Appoints New Chief Medical Officer
- Executive Appointment: Pasithea Therapeutics announced the appointment of Kartik Krishnan as Chief Medical Officer effective May 1, bringing over 20 years of clinical development and pharmacovigilance experience, which is expected to enhance the company's expertise.
- Industry Background: Prior to joining Pasithea, Krishnan served as CEO of OncoNano Medicines, a company focused on developing anti-cancer assets, and this experience will aid Pasithea's strategic development in oncology.
- Clinical Operations Improvement: With extensive experience across clinical operations, Krishnan is expected to drive efficiencies in Pasithea's clinical trials and drug development processes, potentially accelerating the time-to-market for new therapies.
- Company Outlook: This executive change reflects Pasithea's commitment to enhancing its R&D capabilities and market competitiveness, which may attract more investor interest in its future business developments.
See More
FDA Grants Rare Pediatric Disease Designation to PAS-004 for NF1 Treatment
- FDA Designation Progress: Pasithea Therapeutics' PAS-004 has received Rare Pediatric Disease Designation from the FDA for Neurofibromatosis Type 1 (NF1), marking a significant milestone in the company's drug development journey.
- Priority Review Voucher Potential: This designation makes PAS-004 eligible for a Priority Review Voucher upon approval, with recent voucher sales ranging from $150 million to $205 million, potentially providing substantial financial benefits to the company.
- Clinical Trial Advancement: A Phase 1/1b study of PAS-004 is currently underway, targeting adult patients with symptomatic, inoperable, or recurrent NF1-related plexiform neurofibromas, demonstrating the company's proactive exploration in the treatment space.
- Stock Performance: Pasithea's stock closed at $0.7424 on Friday, up 0.87%, reflecting the market's positive response to the company's drug development progress.
See More
Pasithea Receives Rare Pediatric Disease Designation for PAS-004
- FDA Designation Progress: Pasithea Therapeutics' PAS-004 has received Rare Pediatric Disease Designation from the FDA for Neurofibromatosis type 1 (NF1), indicating the drug's potential to address this serious condition affecting approximately 115,000 individuals in the U.S.
- Priority Review Voucher Opportunity: Under the FDA's Priority Review Voucher program, drugs receiving this designation may obtain priority review for subsequent applications, with vouchers previously selling for between $150 million and $205 million in the last year, highlighting significant market potential.
- Clinical Trial Advancement: The company is currently conducting a Phase 1/1b multicenter open-label dose escalation trial of PAS-004 in adult NF1 patients, aimed at assessing the drug's safety and preliminary efficacy, further advancing its clinical development.
- Multiple FDA Designations: PAS-004 has secured Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation, showcasing its broad application potential in treating RASopathies and MAPK pathway-driven tumors, thereby enhancing the company's competitive position in the biotechnology sector.
See More
Pasithea Receives FDA Fast Track Designation for PAS-004
- FDA Fast Track Designation: Pasithea Therapeutics' PAS-004 has received Fast Track designation from the FDA for treating NF1-associated PN, a decision that will expedite drug development and significantly enhance patient access and timeliness of treatment.
- Clinical Trial Progress: The company is currently conducting a Phase 1/1b multicenter open-label dose escalation trial of PAS-004 in adult patients with symptomatic, inoperable, incompletely resected, or recurrent NF1-PN, which is expected to provide new treatment options for patients.
- Market Potential: With 30-50% of NF1 patients harboring PNs that may undergo malignant transformation, the development of PAS-004 not only addresses this unmet medical need but also opens new market opportunities for Pasithea, enhancing its competitiveness in the biotechnology sector.
- FDA Interaction Advantages: The Fast Track designation allows Pasithea to engage in frequent communications with the FDA, supporting rapid feedback during the product development process, thereby improving the efficiency and success rate of clinical trials and further strengthening the company's strategic position in the biopharmaceutical industry.
See More
Pasithea to Present Drug Progress at Oppenheimer Conference
- CEO Presentation Scheduled: Pasithea's CEO Tiago Reis Marques is set to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, from 4:00 to 4:30 PM, showcasing the latest developments in the company's drug pipeline, which is expected to attract investor interest.
- Clinical Trial Updates: The company is conducting Phase 1 trials for PAS-004 targeting advanced cancer patients (NCT06299839) and adult patients with neurofibromatosis type 1 (NF1) (NCT06961565), which will lay the groundwork for future drug approvals and enhance market competitiveness.
- Investor Engagement Opportunities: Management will be available for one-on-one meetings with registered investors during the conference, providing direct engagement that not only boosts investor confidence but may also facilitate future financing opportunities.
- Live Webcast Availability: The presentation will be accessible via a live webcast on the company's investor section of the website, with a replay available post-event, ensuring that investors who cannot attend live can still access critical information, thereby enhancing company transparency and investor relations.
See More
Pasithea Appoints New CMO to Advance PAS-004 Development
- Executive Appointment: Pasithea Therapeutics has appointed Kartik Krishnan as Chief Medical Officer, who will oversee clinical strategy and development with a focus on neurofibromatosis type 1-associated tumors, which is expected to accelerate the development of its lead candidate PAS-004.
- R&D Experience: Krishnan brings over 20 years of experience in clinical development, regulatory strategy, and R&D, having previously worked at OncoNano Medicines, Arcus Biosciences, Genentech, and Amgen, and his experience in developing the FDA-approved MEK inhibitor cobimetinib is anticipated to directly benefit the progression of the PAS-004 program.
- Clinical Trial Progress: Pasithea is currently evaluating PAS-004 in early-stage clinical trials targeting advanced cancers and NF1-related plexiform neurofibromas, indicating the company's potential in the cancer treatment arena.
- Market Outlook: With ongoing evaluations of PAS-004, Pasithea may secure a significant position in the tumor treatment market, particularly in innovative therapies targeting NF1, thereby enhancing its competitive edge.
See More
Pasithea Appoints New Chief Medical Officer
- Executive Appointment: Pasithea Therapeutics announced the appointment of Kartik Krishnan as Chief Medical Officer effective May 1, bringing over 20 years of clinical development and pharmacovigilance experience, which is expected to enhance the company's expertise.
- Industry Background: Prior to joining Pasithea, Krishnan served as CEO of OncoNano Medicines, a company focused on developing anti-cancer assets, and this experience will aid Pasithea's strategic development in oncology.
- Clinical Operations Improvement: With extensive experience across clinical operations, Krishnan is expected to drive efficiencies in Pasithea's clinical trials and drug development processes, potentially accelerating the time-to-market for new therapies.
- Company Outlook: This executive change reflects Pasithea's commitment to enhancing its R&D capabilities and market competitiveness, which may attract more investor interest in its future business developments.
See More
FDA Grants Rare Pediatric Disease Designation to PAS-004 for NF1 Treatment
- FDA Designation Progress: Pasithea Therapeutics' PAS-004 has received Rare Pediatric Disease Designation from the FDA for Neurofibromatosis Type 1 (NF1), marking a significant milestone in the company's drug development journey.
- Priority Review Voucher Potential: This designation makes PAS-004 eligible for a Priority Review Voucher upon approval, with recent voucher sales ranging from $150 million to $205 million, potentially providing substantial financial benefits to the company.
- Clinical Trial Advancement: A Phase 1/1b study of PAS-004 is currently underway, targeting adult patients with symptomatic, inoperable, or recurrent NF1-related plexiform neurofibromas, demonstrating the company's proactive exploration in the treatment space.
- Stock Performance: Pasithea's stock closed at $0.7424 on Friday, up 0.87%, reflecting the market's positive response to the company's drug development progress.
See More
Pasithea Receives Rare Pediatric Disease Designation for PAS-004
- FDA Designation Progress: Pasithea Therapeutics' PAS-004 has received Rare Pediatric Disease Designation from the FDA for Neurofibromatosis type 1 (NF1), indicating the drug's potential to address this serious condition affecting approximately 115,000 individuals in the U.S.
- Priority Review Voucher Opportunity: Under the FDA's Priority Review Voucher program, drugs receiving this designation may obtain priority review for subsequent applications, with vouchers previously selling for between $150 million and $205 million in the last year, highlighting significant market potential.
- Clinical Trial Advancement: The company is currently conducting a Phase 1/1b multicenter open-label dose escalation trial of PAS-004 in adult NF1 patients, aimed at assessing the drug's safety and preliminary efficacy, further advancing its clinical development.
- Multiple FDA Designations: PAS-004 has secured Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation, showcasing its broad application potential in treating RASopathies and MAPK pathway-driven tumors, thereby enhancing the company's competitive position in the biotechnology sector.
See More
Pasithea Receives FDA Fast Track Designation for PAS-004
- FDA Fast Track Designation: Pasithea Therapeutics' PAS-004 has received Fast Track designation from the FDA for treating NF1-associated PN, a decision that will expedite drug development and significantly enhance patient access and timeliness of treatment.
- Clinical Trial Progress: The company is currently conducting a Phase 1/1b multicenter open-label dose escalation trial of PAS-004 in adult patients with symptomatic, inoperable, incompletely resected, or recurrent NF1-PN, which is expected to provide new treatment options for patients.
- Market Potential: With 30-50% of NF1 patients harboring PNs that may undergo malignant transformation, the development of PAS-004 not only addresses this unmet medical need but also opens new market opportunities for Pasithea, enhancing its competitiveness in the biotechnology sector.
- FDA Interaction Advantages: The Fast Track designation allows Pasithea to engage in frequent communications with the FDA, supporting rapid feedback during the product development process, thereby improving the efficiency and success rate of clinical trials and further strengthening the company's strategic position in the biopharmaceutical industry.
See More
Pasithea to Present Drug Progress at Oppenheimer Conference
- CEO Presentation Scheduled: Pasithea's CEO Tiago Reis Marques is set to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, from 4:00 to 4:30 PM, showcasing the latest developments in the company's drug pipeline, which is expected to attract investor interest.
- Clinical Trial Updates: The company is conducting Phase 1 trials for PAS-004 targeting advanced cancer patients (NCT06299839) and adult patients with neurofibromatosis type 1 (NF1) (NCT06961565), which will lay the groundwork for future drug approvals and enhance market competitiveness.
- Investor Engagement Opportunities: Management will be available for one-on-one meetings with registered investors during the conference, providing direct engagement that not only boosts investor confidence but may also facilitate future financing opportunities.
- Live Webcast Availability: The presentation will be accessible via a live webcast on the company's investor section of the website, with a replay available post-event, ensuring that investors who cannot attend live can still access critical information, thereby enhancing company transparency and investor relations.
See More
